SCHEMBL4269573

SCHEMBL4269573

Cc1cccc(C)c1-c1cc(C)c2nc(Nc3ccc(OCCN4CCCC4)cc3)nnc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 20/20 1.00
YES1 P07947 6/20 1.00
PDGFRB P09619 6/20 1.00
EPHB4 P54760 5/20 1.00
KDR P35968 4/20 1.00
ABL1 P00519 3/20 1.00
LCK P06239 2/20 1.00
LYN P07948 2/20 1.00
CYP3A4 P08684 2/20 1.00
CYP2D6 P10635 2/20 1.00
CYP2C19 P33261 2/20 1.00
EGFR P00533 1/20 1.00
RAF1 P04049 1/20 1.00
FYN P06241 1/20 1.00
FGFR1 P11362 1/20 1.00
RPS6KB1 P23443 1/20 1.00
CSK P41240 1/20 1.00
BLK P51451 1/20 1.00
MAP2K1 Q02750 1/20 1.00
TEK Q02763 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4265763 0.95 SRC (1.00) SRCYES1PDGFRBEPHB4KDR
SCHEMBL29385716 0.94 SRC (1.00) SRCYES1PDGFRBEPHB4KDR
SCHEMBL4266197 0.94 SRC (1.00) SRCYES1PDGFRBEPHB4KDR
SCHEMBL4265948 0.94 SRC (1.00) SRCYES1PDGFRBEPHB4KDR
SCHEMBL4271485 0.93 SRC (1.00) SRCYES1PDGFRBEPHB4KDR
SCHEMBL4266596 0.92 SRC (1.00) SRCYES1PDGFRBEPHB4KDR
SCHEMBL4272220 0.92 SRC (1.00) SRCYES1PDGFRBEPHB4KDR
SCHEMBL4269677 0.92 SRC (1.00) SRCYES1PDGFRBEPHB4KDR
SCHEMBL4268405 0.91 SRC (1.00) SRCYES1PDGFRBEPHB4KDR
SCHEMBL4265954 0.91 SRC (1.00) SRCYES1PDGFRBEPHB4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1809614-B1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN INC (US) 2014-05-07 EP disclosed
EP-1809614-B1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN INC (US) 2014-05-07 EP disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 US disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 US disclosed
US-8481536-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2013-07-09 US disclosed
EP-2543376-A1 Benzotriazine inhibitors of kinases Targegen, Inc. (US) 2013-01-09 EP disclosed
EP-2543376-A1 Benzotriazine inhibitors of kinases Targegen, Inc. (US) 2013-01-09 EP disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 US disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 US disclosed
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2011-12-01 US disclosed
US-20110243999-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS TARGEGEN INC. 2011-10-06 US disclosed
US-20110243999-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS TARGEGEN INC. 2011-10-06 US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 US disclosed
US-20090275569-A1 Benzotriazine Inhibitors of Kinases TARGEGEN, INC. 2009-11-05 US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 US disclosed
US-7456176-B2 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2008-11-25 US disclosed
US-20050245524-A1 Benzotriazine inhibitors of kinases TARGEGEN, INC. (US) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294796-A1 BENZOTRIAZINE INHIBITORS OF KINASES SRC, CAMK4, CAMK2G SRC 1/4885YES1 237/4885PDGFRB 221/4885
US-20090275569-A1 Benzotriazine Inhibitors of Kinases SRC, CAMK4, CAMK2G SRC 1/4885YES1 237/4885PDGFRB 221/4885
US-20050245524-A1 Benzotriazine inhibitors of kinases SRC, CAMK4, CAMK2G SRC 1/4885YES1 237/4885PDGFRB 221/4885
US-20110243999-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS AQP3, AQP1, AQP4 SRC 4062/4885YES1 3099/4885PDGFRB 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.